Format

Send to

Choose Destination
Nat Rev Drug Discov. 2014 Nov;13(11):783-4. doi: 10.1038/nrd4435.

Paving the critical path of drug development: the CDER perspective.

Author information

1
Director, Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue Silver Spring, Maryland 20993-0002, USA.

Abstract

Improving the science of drug development and regulation is important in fulfilling the public health mission of the US Food and Drug Administration (FDA). A decade on from the launch of the Critical Path Initiative, the FDA's Center for Drug Evaluation and Research (CDER) is now participating in more than 20 science-driven consortia to achieve this goal.

PMID:
25359359
DOI:
10.1038/nrd4435
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center